Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat and calponin homology domain-containing protein 1 (LRCH1)
- Target
- LRCH1
- Molecular classification
- Other (Scaffold/signaling protein with LRR and calponin homology domain)
01
Overview
Leucine-rich repeat and calponin homology domain-containing protein 1 (LRCH1) is a cytoplasmic protein characterized by an N-terminal leucine-rich repeat (LRR) domain and a C-terminal calponin homology (CH) domain[1][2]. LRCH1 acts as a scaffold or adaptor protein, primarily involved in the regulation of actin cytoskeleton dynamics and immune cell migration. In immune cells, LRCH1 binds and sequesters DOCK8, a guanine exchange factor for CDC42, thereby negatively regulating CDC42 activation and CD4+ T cell migration[2][1]. LRCH1 also negatively regulates cytotoxic T lymphocyte function, natural killer cell activity, and microglial activation through pathways affecting actin dynamics and cytokine production[1]. Associations have been reported between LRCH1 polymorphisms and certain diseases, such as familial hypertrophic cardiomyopathy and De Quervain disease, but its direct therapeutic potential remains unproven[2][3][4]. Currently, there are no drugs targeting LRCH1 or established clinical safety concerns.
- Other names
- CHDC1KIAA1016NP81Neuronal protein 81Leucine-rich repeat and calponin homology domain-containing protein 1LRCH1
02
Mechanism of action
Not applicable (not a direct drug target based on current knowledge)
03
Biological functions
Negative regulation of T cell migrationRegulation of leukocyte migrationRegulation of actin cytoskeletonNegative regulation of GTPase activity (specifically CDC42)Regulation of innate and adaptive immunityCell proliferation and cell division
04
Disease associations
Possible role in autoimmune diseases (e.g., multiple sclerosis model)Cancer (regulation of immune cell infiltration, tumor cell clearance)Inflammation (regulation of microglial activation, ulcerative colitis)Cardiomyopathy (reported genetic association)De Quervain disease (reported genetic association)
Beyond the preview
Go deeper on Leucine-rich repeat and calponin homology domain-containing protein 1 (LRCH1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich repeat and calponin homology domain-containing protein 1 (LRCH1).